Jefferies lifts Hikma target as CMO deal underpins growth story

Jefferies raised its Hikma Pharmaceuticals price target to 2,025p from 1,870p, citing expansion in the company’s contract manufacturing business. The 'buy' rating was kept unchanged, with the new target indicating ~24% upside versus Tuesday’s 1,633p share price (flat).

Analysis

This looks less like a pure earnings upgrade and more like a signal that the market may be undervaluing the quality of Hikma’s fixed-capacity manufacturing footprint. If third-party production is filling underutilized sterile assets, incremental EBITDA should outpace revenue, which is exactly the kind of mix shift that can tighten free-cash-flow conversion and justify a modest rerating versus generic-drug peers.

The second-order effect is competitive, not just company-specific: a stronger outsourced-manufacturing platform can pull share from smaller regional CDMOs that lack scale, compliance history, or customer diversification. But the thesis only works if the business is recurring and capacity-light; if wins require sustained capex, higher working capital, or one-off remediation spend, the economics deteriorate quickly and the market will stop paying up for the story.

Near term, the PT change alone is not a catalyst; the stock may stay range-bound until management proves backlog durability and margin accretion in the next 1-3 months. The contrarian risk is that investors are treating "contract manufacturing" as inherently high quality, when in pharma it can be lumpy, concentrated, and vulnerable to regulatory hiccups. This becomes a real structural rerate only over 6-18 months if utilization, margin, and cash conversion all improve together.

Key Decisions for Investors

• Buy HKMPF on weakness, but only if the next earnings call confirms margin expansion in the contract manufacturing segment; target the 2,000-2,025p area over 3-6 months, and cut the position if the stock loses the 1,550p area on disappointing guidance.
• Relative-value trade: long HKMPF / short VTRS or TEVA over the next quarter to isolate a higher-quality manufacturing mix against ongoing generic pricing pressure; exit if Hikma fails to show operating leverage or if the short basket rerates on sector defensiveness.
• Set an alert for backlog, utilization, and capex commentary at the next print; if capex steps up without a corresponding margin inflection, treat the thesis as a value trap rather than a rerating story.
• No options expression unless liquidity is demonstrably adequate; the cleaner expression here is cash equity or a simple relative-value pair.